B. Bader

发表

Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals

Judith Günther, U. Zügel, B. Bader, 2005 .

EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.

K. Thierauch, Andrea Sturz, Benjamin Bader, 2004, Biochemical and biophysical research communications.

EphB4 cellular kinase activity assayed using an enzymatic protein interaction system.

T. Wehrman, Wei Feng, B. Bader, 2013, Assay and drug development technologies.

Associations of B- and C-Raf with Cholesterol, Phosphatidylserine, and Lipid Second Messengers

J. Nickel, U. Rapp, M. Hekman, 2002, The Journal of Biological Chemistry.

A Dual Estrogen Receptor TR-FRET Assay for Simultaneous Measurement of Steroid Site Binding and Coactivator Recruitment

C. Otto, T. Hilal, B. Bader, 2010, Journal of biomolecular screening.

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Andrea Glasauer, A. Haegebarth, M. Quanz, 2017, ACS chemical biology.

Derives de triazolopyridines

P. Lienau, G. Siemeister, M. Koppitz, 2010 .

Bioorganic synthesis of lipid-modified proteins for the study of signal transduction

Herbert Waldmann, Karsten Kuhn, Alfred Wittinghofer, 2000, Nature.

A cGMP-Dependent Protein Kinase Assay for High Throughput Screening Based on Time-Resolved Fluorescence Resonance Energy Transfer

U. Walter, T. Jarchau, A. Palmetshofer, 2001, Journal of biomolecular screening.

KT5823 Inhibits cGMP-dependent Protein Kinase Activity in Vitro but Not in Intact Human Platelets and Rat Mesangial Cells*

U. Walter, T. Lincoln, M. Glazova, 2000, The Journal of Biological Chemistry.

Synthesis of functional Ras lipoproteins and fluorescent derivatives.

A. Wittinghofer, K. Kuhn, D. Owen, 2001, Journal of the American Chemical Society.

G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol.

C. Otto, K. Prelle, B. Bader, 2008, Endocrinology.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

H. Briem, P. Lienau, U. Klar, 2020, Journal of medicinal chemistry.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

P. Lienau, O. von Ahsen, U. Klar, 2016, Molecular Cancer Therapeutics.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

Targeting RAS oncogenesis with SOS1 inhibitors.

R. Hillig, B. Bader, 2022, Advances in cancer research.

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

H. Briem, G. Siemeister, D. Moosmayer, 2019, Proceedings of the National Academy of Sciences.

High Throughput FISH Screening Identifies Small Molecules That Modulate Oncogenic lncRNA MALAT1 via GSK3B and hnRNPs

Alexander Ulrich, P. Steigemann, B. Bader, 2023, Non-coding RNA.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1

S. Müller, B. Haendler, M. Philpott, 2014, The Journal of Biological Chemistry.

AffinityMapofBromodomainProtein4(BRD4)Interactionswith theHistoneH4TailandtheSmallMoleculeInhibitorJQ1

S. Müller, B. Haendler, M. Philpott, 2014 .

, Tail and the Small Molecule Inhibitor JQ 1 ( BRD 4 ) Interactions with the Histone H 4 Affinity Map of Bromodomain Protein 4 Cell Biology

S. Müller, B. Haendler, M. Philpott, 2014 .

Cell-Based Protein Stabilization Assays for the Detection of Interactions between Small-Molecule Inhibitors and BRD4

Marie Jung, B. Haendler, D. Moosmayer, 2015, Journal of biomolecular screening.

Biochemical Analysis of SopE from Salmonella typhimurium, a Highly Efficient Guanosine Nucleotide Exchange Factor for RhoGTPases*

M. Rudolph, A. Wittinghofer, W. Hardt, 1999, The Journal of Biological Chemistry.

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C

Clara D. Christ, P. Steigemann, H. Briem, 2020, ChemMedChem.

A critical review of fundamental controversies in the field of GPR30 research

C. Otto, P. R. Noppinger, B. Bader, 2010, Steroids.

Discovery of BAY-985 a highly selective TBK1/Ikkε inhibitor.

F. Prinz, H. Briem, D. Panne, 2019, Journal of medicinal chemistry.

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

A. Schlicker, P. Lienau, B. Haendler, 2019, Molecular Cancer Therapeutics.

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

H. Briem, P. Lienau, S. Hammer, 2021, Journal of medicinal chemistry.

Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression

H. Weinmann, M. Plattén, Christina Kober, 2019, Cancer Chemistry.

Coactivator Recruitment A Dual Estrogen Receptor TR-FRET Assay for Simultaneous Measurement of Steroid Site Binding and

C. Otto, T. Hilal, B. Bader, 2013 .

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

H. Briem, P. Lienau, U. Luecking, 2020, Journal of medicinal chemistry.

A one-day, dispense-only IP-One HTRF assay for high-throughput screening of Galphaq protein-coupled receptors: towards cells as reagents.

L. Ketscher, C. Bergsdorf, B. Bader, 2008, Assay and drug development technologies.

Assay Development and High‐Throughput Screening

D. Carettoni, B. Bader, 2021 .

Chemoenzymatic Synthesis of Biotinylated Ras Peptides and Their Use in Membrane Binding Studies of Lipidated Model Proteins by Surface Plasmon Resonance

A. Wittinghofer, H. Waldmann, J. Kuhlmann, 1999 .

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Andrea Glasauer, A. Haegebarth, M. Quanz, 2017, ACS chemical biology.